Intellia Vice President, Disease Biology Sean Burns, M.D., will speak at the 10th meeting on Genome Engineering: CRISPR Frontiers at Cold Spring Harbor Laboratory in Cold Spring Harbor, NY, on Aug. 30. More here: https://lnkd.in/eYhXxAKn #CRISPR #GeneEditing
Intellia Therapeutics, Inc.
Biotechnology Research
Cambridge, Massachusetts 56,549 followers
Developing curative genome editing treatments
Über uns
Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help. Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic. View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .
- Website
-
http://www.intelliatx.com
External link for Intellia Therapeutics, Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- Cambridge, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2014
Standorte
-
Primäre
40 Erie Street
Cambridge, Massachusetts 02139, US
Employees at Intellia Therapeutics, Inc.
Aktualisierungen
-
This morning at the Boston Taiwanese Biotechnology Association (BTBA), Intellia CSO Laura Sepp-Lorenzino, Ph.D., will present the keynote address, “A journey on innovation: Making genetic medicines a reality for patients." The event will take place at the Harvard University Northwest Building in Cambridge, MA. More here: https://lnkd.in/eb-Quj-C #GeneEditing #CRISPR
-
As #IntelliaTurns10, we pause to reflect on why this work matters. It's not just about the science, but the potential impact it has on people living with serious diseases. Our #GenomeJourney has only just begun, and we can't wait to see where it takes us. Tune in for part 4 of our 10th-anniversary series! www.intelliatx.com
-
Excited to announce the newest member of our leadership team, Maria Natale, senior vice president of Commercial. With over 20 years of experience in commercialization of rare disease and specialty medicines, Maria has a proven track record of successful launches across various therapeutic areas, including #hereditaryangioedema. Welcome, Maria! https://lnkd.in/echmQ3wP
-
Meet Elena, a senior scientist in Chemistry and Delivery Sciences. Elena recently celebrated her seventh anniversary with Intellia and shared how her work here has allowed her to reach many of her career goals. Learn more about our employees by following #IntelliaCareerJourneys!
-
#HumansofIntellia: Meet Ryan. He joined Intellia almost three years ago, just a few months after the company released the first-ever clinical data for in vivo gene editing. "It was a big motivator for me to come work here," he says. "And I continue to be impressed by the quality of the science." As a director of Business Development, Ryan scouts for innovative technologies, working closely with the Research and Development team to understand their needs and find academic groups or startups with the right tools to complement Intellia’s platform. Ryan has played a pivotal role in establishing processes for evaluating the technology landscape and guiding Intellia toward promising new partnerships. Notably, his efforts helped to establish a collaboration with ReCode Therapeutics to tackle cystic fibrosis. "There's a lot of excitement and promise around the combined application of each company’s platforms," he says. At the end of the day, what Ryan finds most fulfilling is being able to help a colleague or propel projects forward. "Transforming an idea into something tangible is immensely rewarding and motivates me for the next project."
-
Double digits, double the impact! As we celebrate our 10th anniversary, we look back on the legacy we're building for the future. Our Intellia team shares their insights in part three of our anniversary series. #IntelliaTurns10 #GenomeJourney www.intelliatx.com
-
So far, more than 100 patients have been dosed in clinical trials with NTLA-2001, our investigational in vivo CRISPR-based therapy for the potential treatment of #ATTR #amyloidosis. Want to learn more about our program? Go here: https://lnkd.in/eNJ6ve7e
-
$NTLA News: Today, Intellia announced operational highlights and financial results for the second quarter. Full details here: https://lnkd.in/e8_nQqqq #CRISPR #GeneEditing
-
Our CSO, Laura Sepp-Lorenzino, Ph.D., will be speaking at the Gordon Research Conferences Drug Carriers in Medicine and Biology on Aug. 4 from 7:40 - 8:20 pm in Portland, Maine. Don't miss her talk on "Realizing the Promise of CRISPR Therapeutics"! Details here: https://lnkd.in/evDpbTGf #CRISPR #GeneEditing